NASDAQ
27 days, 11 hours ago 
TARS
Tarsus Pharmaceuticals, INC
8-K: Tarsus Pharmaceuticals Reports Strong Q1 2025 Results Driven by XDEMVY Sales
Tarsus Pharmaceuticals announces a successful first quarter in 2025, highlighted by a 217% year-over-year increase in XDEMVY net product sales and a strengthened financial position following a public equity offering.
Better than expected
 
NASDAQ
27 days, 15 hours ago 
TARS
Tarsus Pharmaceuticals, INC
10-Q: Tarsus Pharmaceuticals Reports Strong Q1 2025 Revenue Growth, Driven by XDEMVY Sales
Tarsus Pharmaceuticals' Q1 2025 revenue surged, fueled by a significant increase in XDEMVY sales, alongside strategic financial moves to bolster its market position.
Delay expected
 
Better than expected
 
NASDAQ
30 days, 11 hours ago 
TARS
Tarsus Pharmaceuticals, INC
DEFA14A: Tarsus Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting
Tarsus Pharmaceuticals will hold its annual stockholders meeting on June 12, 2025, to elect directors, vote on executive compensation, and ratify the appointment of Ernst & Young LLP as its independent accounting firm.
NASDAQ
30 days, 15 hours ago 
TARS
Tarsus Pharmaceuticals, INC
DEF: Tarsus Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting
Tarsus Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on director elections, executive compensation, and auditor ratification.
NASDAQ
63 days, 14 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals CEO Bobak Azamian Sells 6,000 Shares
Bobak Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, sold 6,000 shares of common stock at $50 per share on March 24, 2025, according to a Form 4 filing.
NASDAQ
69 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
69 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals COO Seshadri Neervannan Sells Shares to Cover Tax Obligations
Seshadri Neervannan, COO of Tarsus Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.
NASDAQ
69 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals' General Counsel Sells Shares to Cover Tax Obligations
Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
69 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals Executive Dianne C. Whitfield Sells Shares to Cover Tax Obligations
Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, sold shares of common stock between March 18 and March 20, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
69 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals CEO Bobak Azamian Sells Shares to Cover Tax Obligations
Tarsus Pharmaceuticals' CEO, Bobak R. Azamian, sold shares of common stock to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.
NASDAQ
69 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals CFO Sells Shares to Cover Tax Obligations
Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.
NASDAQ
71 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals CFO Jeffrey Farrow Reports Stock Transactions
Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.
NASDAQ
71 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals CEO Bobak Azamian Exercises Stock Options
Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc., reports the acquisition of common stock through the exercise of restricted stock units.
NASDAQ
71 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals Executive Dianne C. Whitfield Reports Stock Transactions
Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the vesting and settlement of restricted stock units.
NASDAQ
71 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals Executive Wahl Bryan Reports Stock Transactions
General Counsel Wahl Bryan of Tarsus Pharmaceuticals reports the vesting and settlement of restricted stock units and shares acquired through the employee stock purchase plan.
NASDAQ
71 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals COO Seshadri Neervannan Reports Stock Transactions
Chief Operating Officer of Tarsus Pharmaceuticals, Seshadri Neervannan, reports the acquisition of 21,264 shares of common stock and the vesting of several tranches of Restricted Stock Units (RSUs).
NASDAQ
71 days, 9 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals Executive Exercises Stock Options and Acquires Shares
Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, reports the vesting and settlement of restricted stock units and acquisition of shares through the employee stock purchase plan.
NASDAQ
71 days, 15 hours ago 
TARS
Tarsus Pharmaceuticals, INC
8-K: Tarsus Pharmaceuticals Completes $134.8 Million Public Offering After Underwriters Exercise Full Option
Tarsus Pharmaceuticals successfully closes a public offering, generating approximately $134.8 million in net proceeds after the underwriters fully exercised their option to purchase additional shares.
Capital raise
 
NASDAQ
76 days, 14 hours ago 
TARS
Tarsus Pharmaceuticals, INC
8-K: Tarsus Pharmaceuticals Announces $125 Million Upsized Public Offering
Tarsus Pharmaceuticals has priced an upsized public offering of 2,808,988 shares of common stock at $44.50 per share, expecting gross proceeds of approximately $125 million.
Capital raise
 
NASDAQ
78 days, 15 hours ago 
TARS
Tarsus Pharmaceuticals, INC
Form 4: Tarsus Pharmaceuticals Director Exercises Stock Options, Reports Beneficial Ownership
Director Andrew D. Goldberg exercised stock options in Tarsus Pharmaceuticals, increasing his beneficial ownership.
TARS 
Tarsus Pharmaceuticals, INC 
NASDAQ

8-K: Tarsus Pharmaceuticals Completes $134.8 Million Public Offering After Underwriters Exercise Full Option

Sentiment:
 Current Report
 18 March 2025 4:01 PM

Tarsus Pharmaceuticals successfully closes a public offering, generating approximately $134.8 million in net proceeds after the underwriters fully exercised their option to purchase additional shares.

Capital raise
  Tarsus Pharmaceuticals completed a public offering of 2,808,988 shares of common stock at $44.50 per share.  The underwriters exercised their option to purchase an additional 421,348 shares at $41.83 per share.  The company received net proceeds of approximately $134.8 million from the offering. 

Summary
  • Tarsus Pharmaceuticals, Inc. has completed a public offering of its common stock.
  • The offering involved the sale of 2,808,988 shares at a price of $44.50 per share.
  • The underwriters had an option to purchase an additional 421,348 shares at $41.83 per share, which they exercised in full on March 14, 2025.
  • The company sold a total of 3,230,336 shares, including the shares from the underwriters' option.
  • Tarsus Pharmaceuticals received net proceeds of approximately $134.8 million after deducting underwriting discounts, commissions, and offering expenses.
Sentiment

Score: 8

Explanation: The successful completion of the offering and the full exercise of the underwriter option are positive indicators, suggesting strong investor interest and confidence in the company's prospects. The company now has additional capital to execute its business plan.

Positives
  • Tarsus Pharmaceuticals successfully raised approximately $134.8 million in net proceeds.
  • The full exercise of the underwriters' option indicates strong investor demand.
  • The capital injection strengthens the company's financial position.
Industry Context

Follow-on offerings are common in the pharmaceutical industry to raise capital for research and development, clinical trials, or commercialization efforts. The successful completion of this offering suggests investor confidence in Tarsus Pharmaceuticals' prospects.

Comparison to Industry Standards
  • Comparable pharmaceutical companies often utilize public offerings to fund late-stage clinical trials or prepare for product launches.
  • The size of the offering ($134.8 million net proceeds) is within the typical range for companies of Tarsus Pharmaceuticals' size and stage of development.
  • The underwriter discount is standard for this type of transaction.
Stakeholder Impact
  • Shareholders benefit from the increased capital, which can be used to fund growth initiatives.
  • The company is better positioned to execute its strategic objectives.
  • The offering could potentially dilute existing shareholders.
Key Dates
  • March 14, 2025: Underwriters exercised their option in full to purchase additional shares.
  • March 18, 2025: Date of the report.
Keywords
TARS 
Tarsus Pharmaceuticals, INC 
NASDAQ
Sector: TBD
 
Filings with Classifications
Better than expected
1 May 2025 8:07 PM
Earnings Release
  • XDEMVY sales significantly exceeded expectations, demonstrating strong market adoption.
  • The company's net loss decreased compared to the same period last year, indicating improved financial performance.
Better than expected
1 May 2025 4:10 PM
Quarterly Report (10-Q)
  • Revenue was significantly higher than the same quarter last year.
  • The company has a strong cash position.
  • The company is making progress on its clinical pipeline.
Delay expected
1 May 2025 4:10 PM
Quarterly Report (10-Q)
  • The Carpo trial, evaluating TP-05, experienced patient enrollment delays.
Capital raise
18 March 2025 4:01 PM
Current Report
  • Tarsus Pharmaceuticals completed a public offering of 2,808,988 shares of common stock at $44.50 per share.
  • The underwriters exercised their option to purchase an additional 421,348 shares at $41.83 per share.
  • The company received net proceeds of approximately $134.8 million from the offering.
Capital raise
13 March 2025 4:40 PM
Capital Raising Announcement
  • Tarsus Pharmaceuticals is raising capital through a public offering of common stock.
  • The company expects to receive approximately $117.1 million in net proceeds from the offering.
  • The underwriters have an option to purchase additional shares, which could increase the total capital raised.
Better than expected
25 February 2025 7:07 AM
Earnings Release
  • The company's net loss decreased from $135.9 million in 2023 to $115.6 million in 2024.
  • Product sales increased significantly compared to the previous year.
Better than expected
13 January 2025 8:30 AM
Corporate Presentation
  • XDEMVY sales and adoption are exceeding expectations, positioning it as a potential blockbuster.
  • The company is making significant progress in expanding coverage and market reach.
Delay expected
13 November 2024 4:12 PM
Quarterly Report
  • The company experienced delays related to its Carpo trial with topline results pushed out to February 2024 as a result of patient enrollment delays.
Better than expected
13 November 2024 4:12 PM
Quarterly Report
  • The company's product sales significantly exceeded expectations, indicating strong market adoption of XDEMVY.
  • The company's net loss was lower than the same period last year, indicating improved financial performance.
Capital raise
13 November 2024 4:12 PM
Quarterly Report
  • The company may require additional capital to fully develop its product candidates and execute its business strategy.
  • The company's future capital requirements will depend on various factors, including the success of commercialization efforts and the cost of clinical trials.
  • The company may raise additional funds through equity offerings, debt financings, collaborations, strategic alliances, or licensing arrangements.
Better than expected
13 November 2024 4:06 PM
Quarterly Report
  • The company's product sales significantly exceeded the previous year's results.
  • The net loss has decreased compared to the same period last year.
  • The company has secured broad payer coverage, exceeding expectations.
Capital raise
8 August 2024 4:13 PM
Quarterly Report
  • The company may be required to raise additional capital to fund its ongoing operations.
  • The company plans to fund its operations, capital funding and other liquidity needs using existing cash and investments and, to the extent available, cash generated from commercial operations.
Better than expected
8 August 2024 4:13 PM
Quarterly Report
  • The company's revenue growth in Q2 2024 was better than expected, driven by strong XDEMVY sales.
  • The improvement in gross-to-net discounts was better than expected, indicating better pricing and reimbursement strategies.
Better than expected
8 August 2024 4:07 PM
Quarterly Report
  • The company's XDEMVY sales increased by 65% quarter-over-quarter, indicating better than expected market adoption.
  • The gross-to-net discount improved to 44%, which is better than the previous quarter's 55%.
Better than expected
8 May 2024 4:12 PM
Quarterly Report
  • The company's revenue from product sales of XDEMVY significantly exceeded expectations for the first quarter of commercialization.
  • The number of bottles of XDEMVY delivered to patients and the number of eye care providers prescribing the treatment both showed substantial growth.
Delay expected
8 May 2024 4:12 PM
Quarterly Report
  • The company experienced delays related to its Carpo trial with topline results pushed out to February 2024 as a result of patient enrollment delays.
Capital raise
8 May 2024 4:12 PM
Quarterly Report
  • The company completed a follow-on public offering in March 2024, raising net proceeds of $107.7 million.
  • The company may be required to raise additional capital to fund its ongoing operations.
Capital raise
8 May 2024 4:09 PM
Quarterly Report
  • Tarsus completed an approximately $108 million public equity offering in March 2024.
  • The company secured a $200 million non-dilutive credit facility in April 2024, drawing $75 million at close.
Better than expected
8 May 2024 4:09 PM
Quarterly Report
  • The company's net product sales of XDEMVY increased by 89% compared to the previous quarter, indicating better than expected market adoption.
  • The company delivered 26,000 bottles of XDEMVY to patients, a 65% increase over the previous quarter, showing better than expected demand.
  • The company secured multiple commercial payer contracts and is on track for broad commercial coverage by the end of 2024, indicating better than expected progress in market access.
Capital raise
5 March 2024 4:09 PM
Capital Raise Announcement
  • Tarsus Pharmaceuticals raised approximately $107.8 million through a public offering of common stock and pre-funded warrants.
  • The offering included the sale of 3,281,250 shares of common stock and pre-funded warrants to purchase 312,500 shares.
  • The underwriters exercised their option to purchase an additional 468,750 shares.
Capital raise
1 March 2024 5:26 PM
Capital Raise Announcement
  • Tarsus Pharmaceuticals is conducting a public offering of 2,812,500 shares of common stock at $32.00 per share.
  • The company is also offering pre-funded warrants to purchase 312,500 shares at $31.9999 per warrant.
  • The underwriters have a 30-day option to purchase an additional 468,750 shares.
  • The gross proceeds from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
  • The net proceeds to the Company from the Offering are expected to be approximately $93.7 million, after deducting underwriting discounts and commissions and estimated Offering expenses payable by the Company, assuming no exercise by the Underwriters of their option to purchase additional shares of common stock.
Capital raise
27 February 2024 4:02 PM
Annual Results
  • The company states that it may need to obtain substantial additional funding to achieve its goals.
  • The company has a Credit Facility with Hercules and SVB, but may need to raise additional capital through equity offerings, debt financings, collaborations, strategic alliances, or licensing arrangements.
Delay expected
27 February 2024 4:02 PM
Annual Results
  • The company experienced delays in patient enrollment in the Carpo trial, pushing out topline results to February 2024.
Worse than expected
27 February 2024 4:02 PM
Annual Results
  • The company's net loss increased significantly from $62.1 million in 2022 to $135.9 million in 2023, indicating worse than expected financial performance.
Better than expected
26 February 2024 9:18 PM
Annual Results
  • The company exceeded expectations with the rapid uptake of XDEMVY and strong initial sales, indicating a successful product launch.

Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.